The company's earnings per share of $0.27 virtually matched last year's fourth-quarter results and were in line with analysts' estimates. Mylan's revenues in its branded segment deflated over 50%, but the firm's generic revenues rose 6%.
Mylan's full-year earnings of $1.21 per share topped the analysts' estimate by $0.08 and last year's $0.96 figure. Mylan expects to earn between $1.30 and $1.40 per share in the current fiscal year, and is aggressively trying to grow earnings at a 15% long-term rate. These numbers are anticipating the company's July launch of its transdermal fentanyl product, which is the generic pain patch for Johnson & Johnson's
Competition in the acne and other markets are threatening to burst Mylan's earnings bubble. The company has been involved in many patent suits, including recent battles with industry giant Johnson & Johnson and Alza Corporation. These court tussles have clouded launch dates for various Mylan products but will probably not deter the long-term viability of the merchandise.
Mylan and it rivals, such as Teva Pharmaceutical Industries
In the "anything you can do, I can do better" world of drug manufacturing, only one thing is for sure: Teenagers will always have acne that needs to disappear as quickly as it shows up. Mylan must stay close to its generic roots, despite difficult patent fights, if it hopes to reach future earnings goals.
Pop on over to the Mylan discussion board and leave your mark.
Fool contributor Phil Wohl spent more than 12 years on Wall Street and now concentrates his writing on more fictional characters. He has no stake in any firm mentioned above.